Details.
The Augenzentrum Bahnhof Basel provides information about Syfovre, containing the active ingredient pegcetacoplan, which has been approved in the USA for treating advanced dry macular degeneration. Monthly eye injections may slow the rate of deterioration by up to 20%. An improvement in visual acuity is not possible and should not be expected. Approval and use in Switzerland were still unclear on the page. Whether this treatment is suitable must be assessed individually.